Search

Showing "11155" results for ""

CROI: Kaletra less likely to cause fat loss than efavirenz when paired with NRTIs

CROI: Cotrimoxazole prophylaxis reduces risk of death by 41% during first six months of ART

CROI: Integrase inhibitor raltegravir (MK-0518) doubles HIV suppression in treatment-experienced patients at 16 weeks

CROI: Non-AIDS malignancies now more common than AIDS-defining cancers in people with HIV

Scientific evidence alone cannot prove liability in criminal HIV transmission cases

CROI: HIV treatment should not be delayed in TB patients with low CD4 counts, South African study shows

CROI: Further evidence that short-course PMTCT prophylaxis compromises mother's future treatment

CROI: Sexual transmission of HCV not limited to HIV-positive gay men

CROI: Effects of transmitted drug resistance on viral load are drug class specific

CROI: Ugandan study confirms low CD4 count, low body weight, TB and anaemia major risk factors for death after starting ART

CROI: Anti-HBV drug entecavir also active against HIV and promotes antiretroviral resistance

CROI: Haiti is the source of HIV subtype B

CROI: Rate of CD4 decline is a poor guide to the risk of AIDS, say investigators

CROI: Once daily Kaletra may be less effective when viral load above 100,000 copies/ml

CROI: Recent OIs or AIDS strongest predictors of development of resistance in South African first-line failures

CROI: Early weaning and formula feeding puts HIV-exposed infants in resource-limited settings at high risk of severe diarrhoea and death

CROI: New NNRTI, TMC278, demonstrates sustained potency, better CNS and lipid profile than efavirenz, in treatment-naive

CROI: HIV testing in New York's bath houses is feasible and reaches men missed by traditional prevention

Receive the latest HIV research and conference news

Showing "11155" results for ""

CROI: Kaletra less likely to cause fat loss than efavirenz when paired with NRTIs

CROI: Cotrimoxazole prophylaxis reduces risk of death by 41% during first six months of ART

CROI: Integrase inhibitor raltegravir (MK-0518) doubles HIV suppression in treatment-experienced patients at 16 weeks

CROI: Non-AIDS malignancies now more common than AIDS-defining cancers in people with HIV

Scientific evidence alone cannot prove liability in criminal HIV transmission cases

CROI: HIV treatment should not be delayed in TB patients with low CD4 counts, South African study shows

CROI: Further evidence that short-course PMTCT prophylaxis compromises mother's future treatment

CROI: Sexual transmission of HCV not limited to HIV-positive gay men

CROI: Effects of transmitted drug resistance on viral load are drug class specific

CROI: Ugandan study confirms low CD4 count, low body weight, TB and anaemia major risk factors for death after starting ART

CROI: Anti-HBV drug entecavir also active against HIV and promotes antiretroviral resistance

CROI: Haiti is the source of HIV subtype B

CROI: Rate of CD4 decline is a poor guide to the risk of AIDS, say investigators

CROI: Once daily Kaletra may be less effective when viral load above 100,000 copies/ml

CROI: Recent OIs or AIDS strongest predictors of development of resistance in South African first-line failures

CROI: Early weaning and formula feeding puts HIV-exposed infants in resource-limited settings at high risk of severe diarrhoea and death

CROI: New NNRTI, TMC278, demonstrates sustained potency, better CNS and lipid profile than efavirenz, in treatment-naive

CROI: HIV testing in New York's bath houses is feasible and reaches men missed by traditional prevention

Receive the latest HIV research and conference news